Literature DB >> 24890593

Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.

Shivani Singh1, Andre Kubler1, Utpal K Singh2, Ajay Singh2, Harriet Gardiner1, Rajniti Prasad3, Paul T Elkington4, Jon S Friedland5.   

Abstract

Tuberculosis is characterized by extensive destruction and remodelling of the pulmonary extracellular matrix. Stromal cell-derived matrix metalloproteinases (MMPs) are implicated in this process and may be a target for adjunctive immunotherapy. We hypothesized that MMPs are elevated in bronchoalveolar lavage fluid of tuberculosis patients and that antimycobacterial agents may have a modulatory effect on MMP secretion. Concentrations of MMP-1, -2, -3, -7, -8, and -9 were elevated in the bronchoalveolar lavage fluid from tuberculosis patients compared to those in bronchoalveolar lavage fluid from patients with other pulmonary conditions. There was a positive correlation between MMP-3, MMP-7, and MMP-8 and a chest radiological score of cavitation and parenchymal damage. Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Respiratory epithelial cell-derived MMP-1 was suppressed by moxifloxacin and azithromycin, whereas MMP-9 secretion was only decreased by moxifloxacin. In contrast, moxifloxacin and azithromycin both increased MMP-1 and -3 secretion from MRC-5 fibroblasts, demonstrating that the effects of these drugs are cell specific. Isoniazid did not affect MMP secretion. In conclusion, MMPs are elevated in bronchoalveolar lavage fluid from tuberculosis patients and correlate with parameters of tissue destruction. Antimycobacterial agents have a hitherto-undescribed immunomodulatory effect on MMP release by stromal cells.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890593      PMCID: PMC4136059          DOI: 10.1128/AAC.02141-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  65 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.

Authors:  G G Zhanel; A M Noreddin
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

2.  MMPs in tuberculosis: granuloma creators and tissue destroyers.

Authors:  Padmini Salgame
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

3.  A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis.

Authors:  Anna P Ralph; Muhamed Ardian; Andri Wiguna; Graeme P Maguire; Niels G Becker; Glen Drogumuller; Michael J Wilks; Govert Waramori; Emiliana Tjitra; Enny Kenagalem; Gysje J Pontororing; Nicholas M Anstey; Paul M Kelly
Journal:  Thorax       Date:  2010-10       Impact factor: 9.139

4.  Tackling tissue destruction in tuberculosis.

Authors:  Jon S Friedland
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-07-03       Impact factor: 2.184

5.  Tuberculosis immunopathology: the neglected role of extracellular matrix destruction.

Authors:  Paul T Elkington; Jeanine M D'Armiento; Jon S Friedland
Journal:  Sci Transl Med       Date:  2011-02-23       Impact factor: 17.956

6.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice.

Authors:  R D Hautamaki; D K Kobayashi; R M Senior; S D Shapiro
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

7.  Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.

Authors:  Hannah Blau; Keren Klein; Itamar Shalit; Drora Halperin; Ina Fabian
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-09-29       Impact factor: 5.464

8.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

Authors:  Marcus B Conde; Anne Efron; Carla Loredo; Gilvan R Muzy De Souza; Nadja P Graça; Michelle C Cezar; Malathi Ram; Mohammad A Chaudhary; William R Bishai; Afranio L Kritski; Richard E Chaisson
Journal:  Lancet       Date:  2009-04-04       Impact factor: 79.321

9.  TB control in India--efforts, challenges and priorities.

Authors:  R S Sisodia; D K Jain; S S Agarwal; Avdhesh Gupta
Journal:  J Indian Med Assoc       Date:  2011-12

10.  Tuberculosis and poverty: why are the poor at greater risk in India?

Authors:  Olivia Oxlade; Megan Murray
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

View more
  16 in total

1.  Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Julian Sanchez-Bautista; Mariah H Klunk; Michael E Urbanowski; André Kübler; William R Bishai; Paul T Elkington; Sanjay K Jain
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

Review 2.  Mycobacterium tuberculosis infection of the 'non-classical immune cell'.

Authors:  Philippa J Randall; Nai-Jen Hsu; Valerie Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  Immunol Cell Biol       Date:  2015-03-24       Impact factor: 5.126

3.  Effect of Liposome-Encapsulated Dextrazide on Local Regulation of Extracellular Matrix Metabolism in Liver and Lungs of Mice with during Chronic BCG-Induced Granulomatosis.

Authors:  L B Kim; A N Putyatina; G S Russkikh; V A Shkurupy
Journal:  Bull Exp Biol Med       Date:  2021-03-31       Impact factor: 0.804

4.  Matrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral Therapy.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Shiang-Ju Kung; Kebatshabile Nfanyana; Andrew P Steenhoff; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  EBioMedicine       Date:  2015-11-25       Impact factor: 8.143

5.  Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Authors:  Alvaro A Ordonez; Rokeya Tasneen; Supriya Pokkali; Ziyue Xu; Paul J Converse; Mariah H Klunk; Daniel J Mollura; Eric L Nuermberger; Sanjay K Jain
Journal:  Dis Model Mech       Date:  2016-05-26       Impact factor: 5.758

6.  Inhibition of Tissue Matrix Metalloproteinases Interferes with Mycobacterium tuberculosis-Induced Granuloma Formation and Reduces Bacterial Load in a Human Lung Tissue Model.

Authors:  Venkata R Parasa; Jagadeeswara R Muvva; Jeronimo F Rose; Clara Braian; Susanna Brighenti; Maria Lerm
Journal:  Front Microbiol       Date:  2017-12-05       Impact factor: 5.640

7.  Early Secretory Antigenic Target-6 Drives Matrix Metalloproteinase-10 Gene Expression and Secretion in Tuberculosis.

Authors:  Sara Brilha; Tarangini Sathyamoorthy; Laura H Stuttaford; Naomi F Walker; Robert J Wilkinson; Shivani Singh; Rachel C Moores; Paul T Elkington; Jon S Friedland
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

Review 8.  Platelet Activation and the Immune Response to Tuberculosis.

Authors:  Daniela E Kirwan; Deborah L W Chong; Jon S Friedland
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis.

Authors:  Shivani Singh; George Maniakis-Grivas; Utpal K Singh; Radha M Asher; Francesco Mauri; Paul T Elkington; Jon S Friedland
Journal:  J Pathol       Date:  2018-01-18       Impact factor: 7.996

10.  Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Sunhwa Kim; Brian Carr; Mariah H Klunk; Leah Tong; Vikram Saini; Yong S Chang; Matthew McKevitt; Victoria Smith; David L Gossage; Sanjay K Jain
Journal:  PLoS One       Date:  2018-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.